Patient Preferences and Cosmetic Outcomes Following Destructive Treatments for Non-facial Basal Cell Carcinoma: A Mixed Methods Study
- PMID: 39936608
- PMCID: PMC11833252
- DOI: 10.2340/actadv.v105.41325
Patient Preferences and Cosmetic Outcomes Following Destructive Treatments for Non-facial Basal Cell Carcinoma: A Mixed Methods Study
Abstract
The high prevalence of basal cell carcinoma (BCC) entails a substantial burden on healthcare systems. Interest in non-surgical treatment methods for low-risk BCCs, including destructive treatments, is increasing. Dermatologists often highlight suboptimal cosmetic outcomes as drawbacks of destructive treatments, also for non-facial lesions. Patient perspectives regarding scarring and cosmetic outcomes in relation to other relevant factors are largely unknown, yet important to consider in shared decision-making when choosing treatment. This study investigates patient perceptions of scarring following destructive treatments and explores important factors in treatment decisions for non-facial BCCs. Through a mixed-methods design, cosmetic outcomes, patient satisfaction, scarring concerns, and treatment preferences were evaluated within an ongoing randomized clinical trial on destructive treatments for low-risk BCCs. Overall, 157 patients with 425 non-facial scars were assessed. Most patients were not concerned about scar appearance, highlighting a discrepancy compared with dermatologists' general concerns regarding inferior cosmetic outcome. Instead, when opting for specific treatments, patients listed clearance rates as the most important factor, followed by convenience and time consumption. We believe the results are important both in the context of patient-centred care and in "choosing wisely" when deciding between BCC treatments.
Conflict of interest statement
Figures



Similar articles
-
Surgical Treatment of Facial Basal Cell Carcinoma: Patient-Based Assessment of Clinical Outcome in a Prospective Cohort Study.Dermatology. 2016;232(5):550-557. doi: 10.1159/000447354. Epub 2016 Sep 28. Dermatology. 2016. PMID: 27676268
-
What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial.BMC Dermatol. 2012 Oct 4;12:19. doi: 10.1186/1471-5945-12-19. BMC Dermatol. 2012. PMID: 23035730 Free PMC article. Clinical Trial.
-
A retrospective study of 694 Basal Cell Carcinoma excisions to quantify deep margin documentation and clearance compared to histological type and surgical margin.J Plast Reconstr Aesthet Surg. 2019 Nov;72(11):1805-1812. doi: 10.1016/j.bjps.2019.06.002. Epub 2019 Jun 27. J Plast Reconstr Aesthet Surg. 2019. PMID: 31331722
-
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6. Eur J Cancer. 2019. PMID: 31288208 Review.
-
[Basal cell carcinoma surgery].Ugeskr Laeger. 2016 May 16;178(20):V07150603. Ugeskr Laeger. 2016. PMID: 27189106 Review. Danish.
References
-
- Eriksson T TG. Samhällskostnader för hudcancer 2011. Swedish radiation safety authority. Rapportnummer: 2014:49. ISSN: 2000-0456. Available from: www.stralsakerhetsmyndigheten.se
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical